VERIGRAFT Secures Eurostars Grant

VERIGRAFT Secures Eurostars Grant to Advance Personalized 3D-Printed Arterial Grafts

• PREPPER project will integrate 3D printing and tissue engineering
• Swedish and Swiss partners to deploy Euros 1.2 million in ground-breaking work

Gothenburg, February 13, 2025: VERIGRAFT, a leading Swedish biotechnology company has been awarded a prestigious Eurostars grant to lead PREPPER (PREcision Printed PERsonalized Tissue Therapies), a groundbreaking project developing next-generation 3D-printed arterial grafts. Together with Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska University Hospital (Sweden), VERIGRAFT will integrate advanced 3D printing, solution-blown fiber technology, and personalized tissue engineering. The goal is to create customized vascular grafts that mimic natural arteries offering superior durability and seamless integration compared to current synthetic alternatives. The project has secured €1.2 million in funding and brings together internationally recognized experts in their respective fields to drive real innovation in regenerative medicine.

Read More

A Potential Game-Changer not just in Vascular Surgery

PREPPER aims to overcome the major limitations of existing grafts, such as access to human donated material, poor integration and high failure rates. This should pave the way for a first-in-human clinical trial and future commercialization. The technology also has potential applications beyond vascular grafts.

“This Eurostars grant is a major milestone for VERIGRAFT and regenerative medicine. With PREPPER, we are accelerating the future of personalized tissue therapies,” said Dr. Raimund Strehl, CTO of VERIGRAFT. “The global vascular graft market is projected to exceed $4 billion by 2026, and PREPPER positions Europe at the forefront of 3D bioprinting and regenerative medicine.”

About Verigraft

VERIGRAFT is a biotechnology with roots in the Karolinska Institute, VERIGRAFT has grown to become a forerunner in industrialized tissue engineering and advanced regenerative medicine. The company has a strategically focused R&D pipeline of personalized tissues, targeting areas such as cardiovascular and neuronal disease

VERIGRAFT’s headquarters are located close to Gothenburg University and Sweden´s biggest university hospital. Here the company has state-of-the-art preclinical laboratories and offices. VERIGRAFT is led by a team of experienced scientists and entrepreneurs, and is backed by investors from Europe, Asia and the US.

“This project has received funding from the Eurostars-3 joint programme with co-funding from the European Union’s Horizon Europe research and innovation programme. Eurostars is part of the European Partnership on Innovative SMEs”.